<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941223</url>
  </required_header>
  <id_info>
    <org_study_id>Breastblock</org_study_id>
    <nct_id>NCT03941223</nct_id>
  </id_info>
  <brief_title>Regional Anesthesia for Breast Surgery</brief_title>
  <official_title>A Prospective, Randomized Comparison Between Paravertebral and Pectoral Nerve Block on Postoperative Pain, Persistent Post Surgical Pain and Cancer Recurrence After Mastectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcispedale Santa Maria Nuova-IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcispedale Santa Maria Nuova-IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients scheduled for mastecotmy will be randomized to receive either an ultrasound-guided
      double space paravertebral block or a PECSII + parasternal block. In both groups, blocks will
      be performed with 20 ml of ropivacaine 0.75%, plus ropivacaine 0.375% 10 ml for parasternal
      block only.

      Postoperative, all patients will receive a morphine PCA. They will follow at 6, 12, 24 months
      for persistent postoperative surgical pain (PPSP) and cancer recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients scheduled for mastecotmy with or without axillary dissection, will be randomized to
      receive preoperative either an ultrasound-guided double space paravertebral block or a PECSII
      + parasternal block. In both groups, blocks will be performed with 20 ml of ropivacaine
      0.75%, plus ropivacaine 0.375% 10 ml for parasternal block only.

      All the patients also received a general anesthesia induced by propofol and esmeron for
      endotracheal intubation and desflurane for maintaining.

      Sensory block by ice and pinprick test application and maximum spread after 40' from LA
      injection will be registered.

      Postoperative, all patients will receive a morphine PCA, ketorolac 30 mg/12h and paracetamol
      1g each 8h.

      Morphine consumption will be registered. Patients will follow at 6, 12, 24 months for
      persistent postoperative surgical pain (PPSP) and cancer recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine requirement</measure>
    <time_frame>1 day</time_frame>
    <description>Morphine self-administered by a patient controlled device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain</measure>
    <time_frame>2 days</time_frame>
    <description>Pain reporter by a numerical rating scale (NRS) 0-10 (0=no pain, 10=the worst imaginable pain) postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistent Postsurgical pain (PPSP)</measure>
    <time_frame>2 years</time_frame>
    <description>Pain reported by a a numerical rating scale (NRS) 0-10 (0=no pain, 10=the worst imaginable pain) in the follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cancer recurrence</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of cancer recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>pectoral PECS II block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound-guided PECS II block with ropivacaine 0.75% 20 ml (patients N = 75) + Parasternal ultrasound-guided block at T2, T4 levels with ropivacaine 0.375% 10 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paravertebral nerve block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound-guided paravertebral block with ropivacaine 0.75% 20 ml at T1-T2 and T3-T4 levels (10 ml each) (patients N = 75)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PECSII and paravertebral blocks</intervention_name>
    <description>Regional anesthesia for mastectomy outcomes</description>
    <arm_group_label>Paravertebral nerve block</arm_group_label>
    <arm_group_label>pectoral PECS II block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for radical mastectomy for cancer.

          -  age &gt; 18 y-o

          -  Written informed consent

        Exclusion Criteria:

          -  Bilateral surgery

          -  Opioids user

          -  BMI &gt; 35

          -  Postoperative Intensive care
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>gianluca cappelleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AUSL IRCCS Reggio Emilia, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>gianluca cappelleri, MD</last_name>
    <phone>+3905222961</phone>
    <email>gianluca.cappelleri@ausl.re.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>gianluca cappelleri</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AUSL IRCCS Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42120</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>gianluca cappelleri, MD</last_name>
      <email>gianluca.cappelleri@ausl.re.it</email>
    </contact>
    <contact_backup>
      <last_name>gianluca cappelleri, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Arcispedale Santa Maria Nuova-IRCCS</investigator_affiliation>
    <investigator_full_name>Gianluca Cappelleri</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>breast cancer, regional anesthesia, cancer recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

